BiomeBank
- Biotech or pharma, therapeutic R&D
BiomeBank's CONSORTIOME is the world's most advanced microbiome therapeutics platform. The CONSORTIOME platform leverages the world's first approved donor derived microbiome therapy BIOMICTRA,TM is for human first drug discovery. Our pipeline includes three second-generation cultured microbiome therapies that have unrivaled functional capability. The lead candidate is BB265, targeting ulcerative colitis. Undertaking a US $22m Series A capital raise.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}